BioClinica Inks Seven New Trident IWR Deals in First Quarter 2011
BioClinica
announced that Trident IWR (interactive web response) has been
selected
by seven new clients in the first quarter of 2011 to help build and deploy complex trials efficiently without the need for programming.
Trident IWR provides clinical operations personnel a way to directly set up, monitor, and maintain randomization and supplies for their clinical trials, in a less costly manner and in a fraction of the time than previous alternatives. Trident IWR does not require programming for each new clinical trial and it configures both web and voice at the same time..
In December of 2010, GlaxoSmithKline signed an
agreement
with BioClinica to standardize on the Trident IWR system, selecting the technology as a way to manage their global trials across Phase I-IV clinical trials.
“Since we launched Trident IWR in October 2010, BioClinica has received incredible industry-wide response,” said Mark Weinstein, CEO of BioClinica. “With seven companies making the decision to standardize their complex trials with Trident IWR in just the first quarter of 2011 alone, we are happy to confirm that our best-in-class solution is successfully providing the efficiencies, cost savings and overall support needed by today’s top pharmaceutical companies.”
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Using Patient Reported Outcomes in Dermatology Trials
April 25th 2024In part 3 of this video interview with ACT editor Andy Studna, Melissa Mooney, director, eCOA sales engineering, IQVIA sheds light on the unique challenges of dermatology trials and how clinical outcome assessments can be implemented in them.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
